The antiplatelet activity of deferiprone in ß-thalassemia/hemoglobin E patients

Not Applicable

Recruiting

• Conditions: ß- thalassemia/hemoglobin E major or intermedia patients; thalassemia

• Registration Number: TCTR20180718002
• Lead Sponsor: 90th Anniversary of Chulalongkorn University Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2018-07-18
• Study Completion: 2019-04-30
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

ß-thalassemia/hemoglobin E major or intermedia patients.
Male and female from 18-55 years old.
No blood transfusion for at least 4 weeks prior to blood collection.
Do not take any medicines or vitamin or dietary supplements known to affect platelet function (except daily folic acid) at least 2 weeks before each assessment of platelet functions.
Appreciate to participate in this study with sign.

Exclusion Criteria

-Female who are pregnant or breastfeeding.
-Patients with active hepatitis (AST and ALT level are above 3 times the upper limit of normal range), neutropenia, thrombocytopenia, hepatic, renal failure requiring treatment.
-ß-thalassemia patients have chronic diseases: hepatic, renal, heart failure; hypertension, diabetes.
-Taking antiplatelet or anticoagulant drugs

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
% platelet aggregation every meeting time points, before and 2h after taking drug light transmission aggregation test,sP-selectin level every meeting time points, before and after 2 hours of taking d ELISA

Secondary Outcome Measures

Name	Time	Method
ag time, Slope, delaying time of platelet aggregation every meeting time points, before and 2h after taking drug light transmission aggregation test,deferiprone level every meeting time points, before and 2h after taking drug HPLC,NTBI level every meeting time points, before taking drug colorimetric assay,oxLDL level every meeting time points, before taking drug fluorescent measurement with probe NBD-Pen,PT/aPTT every meeting time points, before taking drug clotting time record,Complete blood count 2nd and 4th visit, before taking drug ,Serum ferritin 2nd and 4th visit, before taking drug